The IBD-F Patient Self-Assessment Scale Accurately Depicts the Level of Fatigue and Predicts a Negative Effect on the Quality of Life of Patients With IBD in Clinical Remission

• Published in: Inflammatory bowel diseases Vol. 27; no. 6; pp. 826 - 835
• Main Authors: Varbobitis, Ioannis, Kokkotis, Georgios, Gizis, Michael, Perlepe, Nikoletta, Laoudi, Efrosini, Bletsa, Maria, Bekiari, Despoina, Koutsounas, Ioannis, Kounadis, Georgios, Xourafas, Vassileios, Lagou, Stilliani, Kolios, George, Papakonstantinou, Ioannis, Bamias, Giorgos
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 17-05-2021
• Subjects: Adult; Chronic Disease; Crohn Disease - complications; Fatigue - diagnosis; Fatigue - etiology; Female; Humans; Male; Quality of Life; Reproducibility of Results; Self-Assessment; Severity of Illness Index; Surveys and Questionnaires; questionnaires; fatigue; IBD; quality of life; IBD-F
• DOI: 10.1093/ibd/izaa201
• EISSN: 1536-4844
• ISSN: 1078-0998

Abstract
Background
Fatigue is highly prevalent among patients with inflammatory bowel disease (IBD) and may have an unfavorable impact on quality of life (QoL). The IBD-Fatigue scale (with components SCORE1 and SCORE2) is a recently developed disease-specific questionnaire. We sought to validate a Greek version of IBD-F and use it to assess the severity and characteristics of fatigue and its effect on QoL in our study population.
Methods
The IBD-F scale was validated and used to obtain fatigue-related data from patients with IBD attending a tertiary care hospital. Correlations with other fatigue and QoL instruments were performed.
Results
The Greek IBD-F showed high internal consistency and test-retest reliability (Cronbach’s alpha = 0.901/0.966 and intraclass correlation coefficient = 0.876/0.895 for SCORE1/SCORE2, respectively). A SCORE1 >7.5 suggested “significant” fatigue. In a cohort of 157 patients (mean age = 35.8 y; male patients = 52.2%; patients with Crohn disease = 65.6%), both SCORE1 and SCORE2 were significantly associated with Crohn disease (odds ratio [OR] = 4.17; 95% confidence interval [CI], 2.05-8.47; b = 8.5; 95% CI, 2.8-14.1, respectively), female sex (OR = 7.27; 95% CI, 3.19-16.6; b = 15.3; 95% CI, 9-21.6), and Harvey-Bradshaw Index/Simple Clinical Colitis Activity Index score (OR = 1.22; 95% CI, 1.06-1.39; b = 1.8; 95% CI, 0.9-2.8). A SCORE1 >7.5 was present in 46% of patients in remission, and 82% of patients with a baseline SCORE1 >7.5 remained fatigued at serial measurements. The SCORE1 was significantly associated with impaired QoL (P < 0.001).
Conclusions
The validated IBD-F scale is a useful and applicable instrument for use in the IBD population. A large proportion of patients have significant fatigue, which is maintained longitudinally, independent of inflammatory activity. Fatigue impairs QoL, thus necessitating interventions that may lead to its amelioration in the IBD population.